Leading Pharma, LLC, an Airfield, NJ-based generic pharmaceutical company that manufactures, markets, and distributes products to drug chains, wholesalers, and other channels, completed a $40m growth capital financing.
The transaction was led by Signet Healthcare Partners in addition to Crestline Investors with other investors comprised of Cane Investment Partners and existing members. Concurrently, Nikhil Puri, Managing Director at Signet Healthcare Partners, and Chris Semple, Managing Director at Crestline Investors, will join the board of directors of Leading Pharma’s parent company.
The growth capital will be used to support the company’s research and development (R&D) investments in expanding its diverse pipeline of generic products and to repay existing indebtedness.
Led by Ronald Gold, Co-Founder and Chief Executive Officer, Leading Pharma is a generic pharmaceutical company that purchases, licenses, develops, manufactures, and distributes products to drugstore chains, distributors, wholesalers, mass merchandisers, government agencies and managed care accounts in the U.S. The products are available in various dosage forms across many therapeutic areas under the Leading Pharma label.
Since the acquisition of Excellium Pharmaceutical in 2014, Leading Pharma has evolved from exclusively outsourcing product development work into a vertically-integrated generic pharmaceutical company with internal R&D capabilities.
The company operates a 53,000 square foot manufacturing plant dedicated to oral solid pharmaceuticals.